GLP1R and neoplasm: Recently, the use of gelofusine in connection with the glucagon-like peptide 1 receptor (GLP-1R) ligand 111In-DOTA-exendin-4 resulted in a reduced renal retention by 18% in patients without lowering the tumor uptake [10].